These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 18697367)
1. p53 as a therapeutic target. Staples OD; Steele RJ; Lain S Surgeon; 2008 Aug; 6(4):240-3. PubMed ID: 18697367 [TBL] [Abstract][Full Text] [Related]
2. New p53-based anti-cancer therapeutic strategies. Wiman KG Med Oncol; 1998 Dec; 15(4):222-8. PubMed ID: 9951684 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic exploitation of the p53 pathway. Lane DP; Lain S Trends Mol Med; 2002; 8(4 Suppl):S38-42. PubMed ID: 11927286 [TBL] [Abstract][Full Text] [Related]
4. Small molecules that reactivate mutant p53. Bykov VJ; Selivanova G; Wiman KG Eur J Cancer; 2003 Sep; 39(13):1828-34. PubMed ID: 12932659 [TBL] [Abstract][Full Text] [Related]
5. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005 [TBL] [Abstract][Full Text] [Related]
6. p53: balancing tumour suppression and implications for the clinic. Buganim Y; Rotter V Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621 [TBL] [Abstract][Full Text] [Related]
7. Methods for screening tumors for p53 status and therapeutic exploitation. Tullo A; D'Erchia AM; Sbisà E Expert Rev Mol Diagn; 2003 May; 3(3):289-301. PubMed ID: 12779005 [TBL] [Abstract][Full Text] [Related]
9. The promise and obstacle of p53 as a cancer therapeutic agent. Willis AC; Chen X Curr Mol Med; 2002 Jun; 2(4):329-45. PubMed ID: 12108946 [TBL] [Abstract][Full Text] [Related]
10. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Wiman KG Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of mutant p53 stabilization in cancer. Frum RA; Grossman SR Subcell Biochem; 2014; 85():187-97. PubMed ID: 25201195 [TBL] [Abstract][Full Text] [Related]
12. Targeting p53 in cancer. Chène P Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):151-61. PubMed ID: 12678764 [TBL] [Abstract][Full Text] [Related]
13. The p53 tumour suppressor gene. Steele RJ; Thompson AM; Hall PA; Lane DP Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903 [TBL] [Abstract][Full Text] [Related]
14. p53 and behaviour of colorectal cancer. Goh HS; Chan CS; Khine K; Smith DR Lancet; 1994 Jul; 344(8917):233-4. PubMed ID: 7913159 [TBL] [Abstract][Full Text] [Related]
15. p53 and human cancers. Lane DP Br Med Bull; 1994 Jul; 50(3):582-99. PubMed ID: 7987642 [TBL] [Abstract][Full Text] [Related]
16. p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours. Camplejohn RS; Rutherford J Cell Prolif; 2001 Feb; 34(1):1-14. PubMed ID: 11284915 [TBL] [Abstract][Full Text] [Related]
17. P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A; Thiede C; Huhn D; Wittig B Leukemia; 1996 Jul; 10 Suppl 3():S2-S4. PubMed ID: 8656696 [TBL] [Abstract][Full Text] [Related]
19. Importance of p53 for cancer onset and therapy. Haupt S; Haupt Y Anticancer Drugs; 2006 Aug; 17(7):725-32. PubMed ID: 16926623 [TBL] [Abstract][Full Text] [Related]
20. Improving cancer therapy by non-genotoxic activation of p53. Lain S; Lane D Eur J Cancer; 2003 May; 39(8):1053-60. PubMed ID: 12736103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]